Ultragenyx Pharmaceutical Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on May 7, 2021. The report discloses the entry into a material definitive agreement regarding the potential sale of the company's common stock.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the authorization of a potential equity offering.
Material Changes and Agreements
On May 7, 2021, the Company entered into an Open Market Sale Agreement with Jefferies LLC. Key terms include:
- Offering Capacity: The Company may offer and sell shares of common stock with an aggregate offering price of up to $350,000,000.
- Sale Method: Shares may be sold in "at the market" offerings at prevailing market prices.
- Compensation: Jefferies LLC will receive a commission of up to 3.0% of the gross proceeds from any shares sold.
- Obligations: Neither the Company nor the Agent is obligated to sell or buy any shares under the agreement.
- Registration: The offering is conducted pursuant to a shelf registration statement on Form S-3 (File No. 333-253008), which became effective on February 12, 2021.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or management commentary on operational outlook. The primary risk disclosed is that no assurance can be given that the Company will sell any shares, or if it does, regarding the price, amount, or timing of such sales. The Company has agreed to indemnify the Agent against certain liabilities under the Securities Act of 1933.
Investor Verification Checklist
- Verify the current market price of Ultragenyx common stock (Ticker: RARE) to assess potential dilution impact.
- Review the full text of the Open Market Sale Agreement (Exhibit 1.1) for specific termination rights and conditions.
- Monitor future filings to determine if and when shares are actually sold under this agreement.
- Check the Company's most recent 10-K or 10-Q for actual liquidity and cash position, as this 8-K does not provide those figures.